Patent ID: 7776854

Claim:
A method for treating interstitial pulmonary fibrosis, comprising administering to a patient in need thereof that is suffering from interstitial pulmonary fibrosis an effective amount of a benzothiazole according to formula I or its tautomers, its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, pharmaceutically acceptable salts thereof, and combinations thereof, wherein: X is O, S or NR 0 , with R 0 being H or an C 1 -C 6 alkyl; G is an pyrimidinyl group of the formula wherein L is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, primary, secondary or tertiary amino groups, aminoacyl, aminocarbonyl, amino-(C 1 -C 10 )alkyl, amino-(C 1 -C 10 )-alkyl-aryl, amino-(C 1 -C 10 )alkyl-heteroaryl, C 1 -C 6 alkoxycarbonyl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, sulfonyl, aryl, heteroaryl, 3-8 membered cycloalkyl, optionally containing at least one heteroatom selected from N, O, S, and hydrazido groups, wherein the arrow indicates the point of attachment; R 1 is selected from the group consisting of hydrogen, C 1 -C 6 -alkoxy, C 1 -C 6 -thioalkoxy, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, primary, secondary or tertiary amino groups, aminoacyl, aminocarbonyl, C 1 -C 6 alkoxycarbonyl, aryl, heteroaryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, sulfonyl, sulfonamide or hydrazides; R 2 is selected from the group consisting of hydrogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkyl-aryl, aryl or heteroaryl, C 1 -C 6 -alkyl-heteroaryl, —C(O)—OR 3 , —C(O)—R 3 , —C(O)—NR 3 R 3′ , —(SO 2 )R 3 , with R 3 and R 3′ being independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl.